Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

561
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
561
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

99
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
99
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

370
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
370

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delayed uptake and intra-tree distribution of 2H-labeled irrigation water after repeated experimental summer drought in mature spruce compared with beech.

Tree physiology·2025
Same author

Biomass-Derived Polysilsesquioxane Nanofilament Reinforced Porous Aerogel for Durable Passive Radiative Cooling across All Day and Weather Conditions.

ACS nano·2025
Same author

Gas phase water-initiated droplet-assisted growth and shaping (DAGS) synthesis of poly(ethyl cyanoacrylate) (PECA) nanostructures.

RSC advances·2025
Same author

Organic fibrous nanostructures <i>via</i> the droplet-assisted growth and shaping (DAGS) mechanism.

RSC advances·2025
Same author

The safe and sustainable by design framework applied to graphene-based materials.

Environment international·2025
Same author

Heterogeneous Silicone Nanorods with Region-Specific Functionality.

ACS applied materials & interfaces·2024

Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
07:45

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

1.0K

Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.

Simon P Forster1, Julia Stegmaier2, Rene Spycher3

  • 1Institute of Physical Chemistry (as from 1 January 2014: Department of Chemistry), Business Chemistry Group, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.

Drug Discovery Today
|December 3, 2013
PubMed
Summary
This summary is machine-generated.

Virtual pharmaceutical companies (VPCs) offer a novel R&D collaboration model for the pharmaceutical industry. Investing in VPCs presents a particularly promising strategy for big pharma to navigate challenges in drug development.

More Related Videos

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

5.7K
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

23.8K

Related Experiment Videos

Last Updated: May 5, 2026

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
07:45

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

1.0K
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

5.7K
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

23.8K

Area of Science:

  • Pharmaceutical industry innovation
  • Drug development strategies
  • Biotechnology management

Background:

  • Declining internal R&D success rates and the diminishing blockbuster model challenge the pharmaceutical industry.
  • Traditional R&D collaborations often involve biotech startups, but a new model has emerged.
  • Virtual pharmaceutical companies (VPCs) represent a flexible R&D collaboration concept.

Purpose of the Study:

  • To define the characteristics of virtual pharmaceutical companies (VPCs).
  • To propose how large pharmaceutical companies can utilize VPCs for R&D.
  • To introduce five distinct modes of collaboration between big pharma and VPCs.

Main Methods:

  • Literature review and conceptual analysis of the VPC model.
  • Identification and description of key VPC characteristics.
  • Development of a framework for big pharma-VPC collaboration modes.

Main Results:

  • VPCs are characterized by experienced management teams and a flexible operational structure.
  • Five potential collaboration modes are presented: licensing, co-development, service provision, spin-off creation, and investing.
  • The investing mode is identified as particularly advantageous for big pharma.

Conclusions:

  • VPCs offer a unique approach to pharmaceutical R&D, distinct from traditional biotech collaborations.
  • Big pharma can strategically leverage VPCs through various collaboration models.
  • Investing in VPCs emerges as a key strategy for enhancing pharmaceutical R&D outcomes.